Skip to main content
AmigoFish

Pharmaceutical Executive

Pharmaceutical Executive PodcastAudio

Format:
Podcast
New episodes:
Daily
Typical length:
about 3 minutes
Latest episode:
Not rated yet

About this show

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com (http://PharmExec.com) to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Show details and episodes come from the publisher's public feed at audioboom.com. Last updated . Names, artwork and text belong to their publishers.

Cosmos

Similar by topic and creator

See the full Cosmos

Similar shows

See all Science shows

Explore more

Episodes

  • Pharmaceutical Executive Daily: FDA Approves Cosentyx and Wilserdly

    · 3 min

    Gilead signs royalty-free licensing deals to broaden Ebola antiviral access, FDA approves Cosentyx for polymyalgia rheumatica and Wilserdly for ESR1-mutated breast cancer, and Infinitus’s Ankit Jain talks agentic AI’s role in pharma’s commercial model.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Approves Three New Therapies

    · 3 min

    FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kevin Caldwell joins The Ron Lanton Report on rebuilding bone marrow transplants around deceased-donor marrow.

    Not rated yet
  • The Ron Lanton Report: Ossium Health's Bone Marrow Bank

    · 23 min

    Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Shelves CNPV Program

    · 1 min

    FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.

    Not rated yet
  • Pharmaceutical Executive Daily: Moderna Outlines Growth Plan at 2026 Analyst Day

    · 2 min

    Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Approves Pimjetmi

    · 2 min

    FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Requires Safety Label Update on GLP-1 Receptor Agonist

    · 2 min

    FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.

    Not rated yet
  • Pharmaceutical Executive Daily: argenx Acquires Unnatural Products Inc.

    · 2 min

    argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Rybrevant Faspro

    · 2 min

    Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.

    Not rated yet
  • Pharmaceutical Executive Daily: Egetis Sells Priority Review Voucher for $190 Million

    · 2 min

    ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics as Egetis separately sells its priority review voucher for $190 million, Novartis exits its BrainTransporter deal with BioArctic 14 months after signing, and Ignite Proteomics’ Dr. Brian Corgiat on improving how tumors are tested after recurrence.

    Not rated yet
  • Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie

    · 2 min

    How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Approves Voceryq

    · 2 min

    FDA grants accelerated approval to INOVIO’s Voceryq to reduce surgical burden in recurrent respiratory papillomatosis, Brox.AI’s Hamish Brocklebank on the three levels of digital clone use cases in pharma, and CytoDyn’s Dr. Jay Lalezari on his path from HIV clinician to CEO.

    Not rated yet
  • States Take Center Stage in the Drug Pricing Fight

    · 32 min

    In this episode of the Pharmaceutical Executive podcast, Scott LaGanga, executive vice president of state advocacy at PhRMA, discusses the expanding influence of state policymaking on drug pricing, pharmacy benefit manager reform, and efforts to translate policy changes into lower out-of-pocket costs for patients. Joining Mike Christel, group managing editor, MJH Life Sciences, LaGanga also dives into the potential impact of tomorrow's U.S. midterm elections in shaping the next wave of drug pricing policy in state capitals as much as in Washington. Noting the high stakes, LaGanga explains why turnover in governors’ offices and state legislatures puts fresh urgency on educating policymakers about the pharmaceutical supply chain — and how decisions in states can move quickly and spread across the country. He also considers how the presidential campaign cycle that follows could bring local health care access and affordability concerns further into the national debate.

    Not rated yet
  • Pharmaceutical Executive Daily: Pathos AI Enters Collaboration with Bristol Myers Squibb

    · 2 min

    Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.

    Not rated yet
  • The Ron Lanton Report: A Conversation with Dr. Nadine Zawadzki

    · 37 min

    Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.

    Not rated yet
  • Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act

    · 2 min

    Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.

    Not rated yet
  • Building Biopharma Manufacturing for Speed, Scale, and Flexibility

    · 37 min

    Biopharma manufacturing today is being asked to move faster, accommodate increasingly complex modalities, and respond more readily to changing development timelines and demand forecasts — all while maintaining reliable, compliant, and cost-effective supply. In this episode of the Pharm Exec Podcast, Dave Maraldo, Ph.D., executive vice president and president of the Merck Manufacturing Division, draws on 27 years at the company to explore that evolution. He discusses Merck’s major U.S. capacity investments; its approach to balancing internal capabilities with strategic manufacturing partners; and the closer integration of research, development, and production. Joining Mike Christel, group managing editor, MJH Life Sciences, Maraldo also examines the practical impact of digital tools and artificial intelligence and how Merck is building greater agility and resilience into its global supply network. He reflects ahead as well on what the next generation of manufacturing talent will require and why he thinks patient needs will move closer and closer to the shop floor.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.

    · 2 min

    FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Approves Hibsago

    · 2 min

    A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.

    Not rated yet
  • Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli

    · 2 min

    METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA grants accelerated approval to GSK’s Jemperli for MSI-H/dMMR locally advanced rectal cancer.

    Not rated yet